Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 21Myelodysplastic Syndromes 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia 14Multiple Myeloma 12Lymphoma 11Leukemia, Lymphocytic, Chronic, B-Cell 11Hodgkin Disease 11Lymphoma, Non-Hodgkin 10Leukemia, Myeloid, Chronic-Phase 8Primary Myelofibrosis 7Neoplasms, Plasma Cell 7Myeloproliferative Disorders 7Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Leukemia, Myelomonocytic, Chronic 7Congenital Abnormalities 7Lymphoma, Follicular 6Leukemia, Myeloid, Accelerated Phase 6Hematologic Neoplasms 6Blast Crisis 6Sezary Syndrome 5Mycosis Fungoides 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Burkitt Lymphoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, T-Cell, Cutaneous 4

Interventions

Bortezomib 3filanesib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Lenalidomide 2Dexamethasone 2sargramostim 1montanide ISA 51 1merphos 1liposomal doxorubicin 1ixazomib 1itacitinib 1incomplete Freund's adjuvant 1fludarabine phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Steroids 1Stem Cell Transplantation 1Sirolimus 1Proteasome Inhibitors 1Methotrexate 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Plasma Cell × Tacrolimus × Clear all
NCT01163357 2025-03-26

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

City of Hope Medical Center

Phase 1 Completed
18 enrolled
Other hematologic neoplasmPlasma cell

Chromosome 17 deletion, Leukemia, Plasma Cell, Multiple Myeloma

NCT02504359 2020-11-23

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

OHSU Knight Cancer Institute

Phase 1 Completed
11 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡